Christine St.Clare Sells 4,000 Shares of Tilray Inc (NASDAQ:TLRY) Stock

Tilray Inc (NASDAQ:TLRY) Director Christine St.Clare sold 4,000 shares of the firm’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $50.01, for a total value of $200,040.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Shares of TLRY stock opened at $46.81 on Wednesday. The firm has a 50 day moving average of $43.44. The company has a debt-to-equity ratio of 1.13, a current ratio of 2.35 and a quick ratio of 2.06. Tilray Inc has a twelve month low of $20.10 and a twelve month high of $300.00. The company has a market cap of $4.55 billion and a P/E ratio of -57.09.

Tilray (NASDAQ:TLRY) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.27) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.25) by ($0.02). Tilray had a negative net margin of 159.09% and a negative return on equity of 43.71%. The company had revenue of $23.00 million during the quarter, compared to the consensus estimate of $20.50 million. Tilray’s revenue for the quarter was up 194.9% on a year-over-year basis. Sell-side analysts predict that Tilray Inc will post -0.89 earnings per share for the current fiscal year.

TLRY has been the subject of a number of recent research reports. Alliance Global Partners initiated coverage on Tilray in a research note on Monday, May 13th. They set a “neutral” rating and a $50.00 price target for the company. Piper Jaffray Companies cut their price target on Tilray from $84.00 to $72.00 and set an “overweight” rating for the company in a research note on Wednesday, May 15th. Oppenheimer initiated coverage on Tilray in a research note on Tuesday, June 4th. They set a “market perform” rating for the company. Stifel Nicolaus initiated coverage on Tilray in a research note on Wednesday, June 5th. They set a “hold” rating and a $37.00 price target for the company. Finally, Jefferies Financial Group initiated coverage on Tilray in a research note on Friday, March 8th. They set an “underperform” rating and a $61.00 price target for the company. Three research analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. Tilray currently has a consensus rating of “Hold” and an average price target of $79.27.

Several hedge funds have recently modified their holdings of TLRY. Lee Financial Co bought a new position in shares of Tilray in the 1st quarter valued at approximately $25,000. Quantamental Technologies LLC bought a new position in shares of Tilray in the 1st quarter valued at approximately $26,000. Toronto Dominion Bank bought a new position in shares of Tilray in the 4th quarter valued at approximately $27,000. PNC Financial Services Group Inc. raised its stake in shares of Tilray by 105.8% in the 1st quarter. PNC Financial Services Group Inc. now owns 463 shares of the company’s stock valued at $30,000 after acquiring an additional 238 shares in the last quarter. Finally, Synovus Financial Corp grew its holdings in Tilray by 2,500.0% in the 1st quarter. Synovus Financial Corp now owns 1,040 shares of the company’s stock valued at $69,000 after buying an additional 1,000 shares during the last quarter. 2.10% of the stock is currently owned by institutional investors and hedge funds.

About Tilray

Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.

Read More: How to interpret Moving Average Convergence Divergence (MACD)

Insider Buying and Selling by Quarter for Tilray (NASDAQ:TLRY)

Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.